

With SYFOVRE, the path to access is clearly defined



99% of patients covered across Medicare, Medicaid, and commercial plans have first-line payer access to SYFOVRE for its approved indication^{1,a}

Visit AccessSupportNavigator.SyfovreECP.com for resources that support the path to SYFOVRE access!



^aBased on a review of requirements for covered lives across government plans (Medicare Fee-for-Service, Medicare Advantage, and Medicaid), commercial plans, and public employer plans as of June 2026 from Policy Reporter by Valeris. Prior authorization may still be required for SYFOVRE.¹
Reference: 1. Data on file. Apellis Pharmaceuticals, Inc.